What is the dose of Targocid (Teicoplanin) in a patient with Acute Kidney Injury?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Teicoplanin Dosing in Acute Kidney Injury

For patients with acute kidney injury, teicoplanin should be administered with a loading dose of 6-12 mg/kg every 12 hours for three doses, followed by a maintenance dose of 6-12 mg/kg once daily with dosing interval adjustments based on renal function severity. 1

Initial Loading Dose

  • A loading dose of 25-30 mg/kg (based on actual body weight) is recommended for critically ill patients to rapidly achieve therapeutic drug levels due to expanded extracellular volume related to fluid resuscitation 1
  • Loading doses of antimicrobials with low volumes of distribution (including teicoplanin) are not affected by alterations in renal function 1
  • For serious infections, use the higher end of the dosing range (10-12 mg/kg) for the loading doses 1

Maintenance Dosing Based on Renal Function

  • For moderate renal impairment: 6-12 mg/kg once daily 1, 2
  • For severe renal impairment: 6-12 mg/kg every 2-3 days 3
  • For patients on hemodialysis: 6-12 mg/kg every 3 days or post-dialysis 4

Target Trough Concentrations

  • Target trough concentration (Cmin) should be 15-30 μg/ml for serious infections 2
  • Pre-dose monitoring of trough concentrations is recommended to ensure therapeutic levels 1
  • Achievement of Cmin ≥15 μg/ml without delay is necessary to improve clinical outcomes in patients with renal dysfunction 2

Monitoring Recommendations

  • Measure trough levels before the 4th dose (after completing loading doses) 2
  • For patients with AKI, more frequent monitoring may be required due to changing renal function 4
  • Adjust subsequent doses based on measured trough concentrations and clinical response 2

Important Considerations

  • The elimination half-life of teicoplanin increases significantly with decreasing renal function (from 41 hours in normal renal function to 163 hours in anuric patients) 4
  • Renal clearance of teicoplanin correlates closely with creatinine clearance 4, 3
  • Despite higher trough concentrations in renal dysfunction, nephrotoxicity rates remain acceptable when maintained within the 15-30 μg/ml range 2

Common Pitfalls to Avoid

  • Inadequate loading doses leading to delayed achievement of therapeutic levels 1, 2
  • Failure to adjust maintenance dosing intervals in severe renal dysfunction 4, 3
  • Insufficient monitoring of trough concentrations, especially in patients with changing renal function 2
  • Not considering the extended half-life of teicoplanin in renal dysfunction when planning dosing intervals 4

Remember that while the loading dose remains unchanged regardless of renal function, the maintenance dosing interval needs to be extended as renal function declines 4, 3.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016

Research

Pharmacokinetics of teicoplanin in renal failure.

Antimicrobial agents and chemotherapy, 1987

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.